Wall Street analysts expect ImmunoGen, Inc. (NASDAQ:IMGN) to post earnings of ($0.07) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for ImmunoGen’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.09). ImmunoGen reported earnings of ($0.39) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 82.1%. The business is expected to issue its next quarterly earnings results on Friday, February 16th.
On average, analysts expect that ImmunoGen will report full-year earnings of ($0.97) per share for the current year, with EPS estimates ranging from ($1.01) to ($0.93). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.19) to ($0.77). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for ImmunoGen.
ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.42). The company had revenue of $8.50 million during the quarter, compared to analysts’ expectations of $26.09 million. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business earned ($0.51) earnings per share.
Hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its stake in ImmunoGen by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 331,898 shares of the biotechnology company’s stock valued at $2,360,000 after buying an additional 1,919 shares during the last quarter. Royal Bank of Canada lifted its stake in ImmunoGen by 789.0% in the second quarter. Royal Bank of Canada now owns 154,432 shares of the biotechnology company’s stock valued at $1,098,000 after buying an additional 137,061 shares during the last quarter. Chicago Equity Partners LLC lifted its stake in ImmunoGen by 124.7% in the third quarter. Chicago Equity Partners LLC now owns 490,635 shares of the biotechnology company’s stock valued at $3,753,000 after buying an additional 272,315 shares during the last quarter. OxFORD Asset Management LLP purchased a new stake in ImmunoGen in the second quarter valued at approximately $506,000. Finally, Bank of Nova Scotia purchased a new stake in ImmunoGen in the second quarter valued at approximately $591,000. Institutional investors own 68.02% of the company’s stock.
ImmunoGen (IMGN) opened at $6.74 on Monday. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. The stock has a market capitalization of $1,040.00, a P/E ratio of -5.18 and a beta of 2.20. ImmunoGen has a fifty-two week low of $2.20 and a fifty-two week high of $8.84.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/0-07-eps-expected-for-immunogen-inc-imgn-this-quarter/1812932.html.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with our FREE daily email newsletter.